Swallowable drug delivery device and method of delivery
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61M-031/00
A61K-031/155
A61M-005/20
A61K-038/26
A61K-038/27
A61K-038/28
A61K-009/48
A61M-005/168
A61K-038/22
A61K-045/06
A61K-038/29
A61K-009/00
A61K-038/17
A61M-005/172
A61M-005/14
A61M-005/142
출원번호
US-0507579
(2014-10-06)
등록번호
US-10039908
(2018-08-07)
발명자
/ 주소
Imran, Mir
출원인 / 주소
Rani Therapeutics, LLC
대리인 / 주소
Wilson, Sonsini, Goodrich & Rosati
인용정보
피인용 횟수 :
0인용 특허 :
75
초록▼
Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Some embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. The device compri
Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Some embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. The device comprises a capsule sized to be swallowed and pass through the intestinal tract. The capsule can include at least one guide tube, one or more tissue penetrating members positioned in the guide tube, a delivery member, an actuating mechanism and a release element. The release element degrades upon exposure to various conditions in the intestine so as to release and actuate the actuating mechanism. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
대표청구항▼
1. A method for delivering a therapeutic agent into a wall of the small intestine of a patient, the method comprising: swallowing a drug delivery device comprising a capsule, an expandable member and a therapeutic agent preparation shaped as a solid tissue penetrating member, the tissue penetrating
1. A method for delivering a therapeutic agent into a wall of the small intestine of a patient, the method comprising: swallowing a drug delivery device comprising a capsule, an expandable member and a therapeutic agent preparation shaped as a solid tissue penetrating member, the tissue penetrating member coupled to the expandable member by an advancement member that advances the tissue penetrating member into the wall of the small intestine upon expansion of the expandable member, an end of the advancement member detachably engaging a non-tissue penetrating end of the tissue penetrating member, wherein the end of the advancement member engaging the tissue penetrating member has a larger horizontal surface area than the non-tissue penetrating end of the tissue penetrating member; and expanding the expandable member responsive to a condition in the small intestine to apply a force to a solid surface of the tissue penetrating member using the advancement member so as to insert the tissue penetrating member into the wall of the small intestine where it remains and degrades to release the therapeutic agent into the patient's blood stream. 2. The method of claim 1, wherein the condition is a selected pH. 3. The method of claim 2, wherein the pH is above about 7.1. 4. The method of claim 1, wherein the therapeutic agent comprises a therapeutically effective dose of insulin for treatment of diabetes or a glucose regulation disorder; the method further comprising: using the dose of delivered insulin to control a blood glucose level of the patient without injecting insulin into the patient. 5. The method of claim 1, wherein the therapeutic agent comprises a therapeutically effective dose of an incretin for treatment of diabetes or a glucose regulation disorder; the method further comprising: using the dose of delivered incretin to control a blood glucose level of the patient without injecting insulin into the patient. 6. The method of claim 1, wherein the therapeutic agent comprises a therapeutically effective dose of an incretin and a therapeutically effective dose of a biguanide for treatment of diabetes or a glucose regulation disorder; the method further comprising: using the doses of delivered incretin and biguanide to control a blood glucose level of the patient. 7. The method of claim 6, wherein the incretin comprises exenatide and the biguanide comprises metformin. 8. The method of claim 7, wherein the dose of the incretin is matched to the dose of biguanide to produce an improved level of blood glucose control for an extended period. 9. The method of claim 8, wherein the extended period is up to about a day. 10. The method of claim 1, wherein the expandable member comprises an expandable balloon. 11. A method for delivering a therapeutic agent into a wall of the small intestine of a patient, the method comprising: swallowing a drug delivery device comprising a capsule, an expandable member and a therapeutic agent preparation shaped as a tissue penetrating member having a shaft and a tissue penetrating end, the tissue penetrating member coupled to the expandable member by an advancement member that advances the tissue penetrating member into the wall of the small intestine upon expansion of the expandable member, an end of the advancement member detachably engaging a non-tissue penetrating end of the tissue penetrating member, wherein the end of the advancement member engaging the tissue penetrating member has a larger horizontal surface area than the non-tissue penetrating end of the tissue penetrating member; and expanding the expandable member responsive to a condition in the small intestine to apply a force to a surface of the tissue penetrating member using the advancement member so as to insert the tissue penetrating member into the wall of the small intestine where it remains and degrades to release the therapeutic agent into the patient's blood stream. 12. The method of claim 11, wherein the condition is a selected pH. 13. The method of claim 12, wherein the pH is above about 7.1. 14. The method of claim 11, wherein the therapeutic agent comprises a therapeutically effective dose of insulin for treatment of diabetes or a glucose regulation disorder; the method further comprising: using the dose of delivered insulin to control a blood glucose level of the patient without injecting insulin into the patient. 15. The method of claim 11, wherein the therapeutic agent comprises a therapeutically effective dose of an incretin for treatment of diabetes or a glucose regulation disorder; the method further comprising: using the dose of delivered incretin to control a blood glucose level of the patient without injecting insulin into the patient. 16. The method of claim 11, wherein the expandable member comprises an expandable balloon. 17. A method for delivering a therapeutic agent into a wall of the small intestine of a patient, the method comprising: swallowing a drug delivery device comprising a capsule, an expandable member and a therapeutic agent preparation shaped as a tissue penetrating member; the expandable member disposed in the capsule; andexpanding the expandable member responsive to a condition in the small intestine to apply a force to a solid surface of the therapeutic agent preparation so as to insert the tissue penetrating member into the wall of the small intestine where it remains and degrades to release the therapeutic agent into the patient's blood stream, and wherein when the expandable member expands it breaks apart at least a portion of the capsule. 18. The method of claim 17, wherein the expandable member is a balloon.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (75)
Kink, John A.; Worledge, Katherine L.; Stafford, Douglas C., Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease.
Wright Jeremy C. (Los Altos CA) Eckenhoff James B. (Los Altos CA) Maruyama Frederick H. (San Jose CA) Peery John R. (Stanford CA), Delivery system comprising means for controlling internal pressure.
Lewkowicz,Shlomo; Gat,Daniel; Kraizer,Yehudit; Gilad,Zvika; Leuw,David; Meron,Gavriel; Glukhovsky,Arkady, Device and method for examining a body lumen.
Hugemann Berhhard (Frankfurt am Main DEX) Schuster Otto (Bad Soden DEX), Device for the release of substances at defined locations in the alimentary tract.
Pasricha Pankaj J. (Columbia MD) Kalloo Anthony N. (Glenndale MD), Device for treating gastrointestinal muscle disorders and other smooth muscle dysfunction.
Imran, Mir A.; Herrmann, Peter; Syed, Baber; Williams, Timothy H.; Ong, Chang Jin; Method, Greg, Device, system and methods for the oral delivery of therapeutic compounds.
Imran, Mir; Herrmann, Peter; Syed, Baber; Williams, Timothy H.; Ong, Chang Jin; Method, Greg, Device, system and methods for the oral delivery of therapeutic compounds.
Prausnitz, Mark R.; Allen, Mark G.; Henry, Sebastien; McAllister, Devin V.; Ackley, Donald E.; Jackson, Thomas, Devices and methods for enhanced microneedle penetration of biological barriers.
Yokoi,Takeshi; Takizawa,Hironobu; Segawa,Hidetake; Adachi,Hideyuki, Encapsulated medical device and method of examining, curing, and treating internal region of body cavity using encapsulated medical device.
Lehmann Grard (Neuville de Poitou FRX) Metais Jol (Monts Sur Guesnes FRX) Meunier Jean-Francois (Noisy le Grand FRX) Gautier Jean-Philippe (Ozoir la Ferriere FRX), Implantable drug-dispensing capsule and system facilitating its use.
Truex Buehl E. (Glendora CA) Gibson Scott R. (Granada Hills CA) Weinberg Alvin H. (Moorpark CA), Implantable medical device having shielded and filtered feedthrough assembly and methods for making such assembly.
Brister, Mark C.; Quintana, Nelson; Patel, Kaushik A.; Drake, Neil R.; Llevares, Antonio C.; Markovic, Dubravka; Rasdal, Andrew P.; VandenBerg, Amy D. L., Intragastric device.
Saffran Murray (Toledo OH) Neckers Douglas C. (Perrysburg OH), Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointest.
Nicolaides Ernest D. (Ann Arbor MI) Tinney Francis J. (Ann Arbor MI) Kaltenbronn James S. (Ann Arbor MI) DeJohn Dana E. (Ann Arbor MI) Lunney Elizabeth A. (Ann Arbor MI) Roark W. Howard (Ann Arbor MI, Modified tripeptides.
Eckenhoff ; deceased James B. ; Holladay Leslie A. ; Leonard ; Jr. John Joseph ; Leung Iris K. M. ; Tao Sally A. ; Magruder Judy A. ; Carr John P. ; Wright Jeremy, Peptide/protein suspending formulations.
Imran, Mir, Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
Imran, Mir, Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
Imran, Mir, Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
Imran, Mir, Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
Imran, Mir, Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
Imran, Mir, Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.